newsfilter
← Latest News
Business Wire·

Enrollment Begins in FORESEE Clinical Trial Using Biocept's CNSide™ to Evaluate Patients with Leptomeningeal Metastases

Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company's proprietary cerebrospinal